Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 2/2011

01-02-2011 | Review Article

Evaluation of current therapeutic strategies in Behçet’s disease

Authors: Iliana Alexoudi, Violetta Kapsimali, Aristides Vaiopoulos, Meletios Kanakis, George Vaiopoulos

Published in: Clinical Rheumatology | Issue 2/2011

Login to get access

Abstract

Behçet’s disease (BD) is a chronic relapsing vasculitis with multifunctional pathogenesis. The mucocutaneous and ocular lesions are the commonest manifestations, but BD also affects the musculoskeletal, intestinal, cardiac, and central nervous system. BD therapy is based on the suppression of the inflammatory process, using immunomodulating and immunosuppressive agents. In selected cases, invasive procedures may be required.
Literature
1.
Alpsoy E, Akman A (2009) Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693–702CrossRefPubMed
2.
Ahmad T, Wallace GR, James T et al (2003) Mapping the HLA association in Behçet’s disease: a role for tumor necrosis factor polymorphisms? Arth Rheum 48:807–813CrossRef
3.
Ceyran H, Akcali Y, Kahraman C (2003) Surgical treatment of vasculo-Behçet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 32:149–153CrossRefPubMed
4.
Kapsimali V, Kanakis M, Vaiopoulos G, et al (2010) Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol (in press)
5.
Calamia KT, Kaklamanis PG (2008) Behçet’s disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10:349–355CrossRefPubMed
6.
Gul A (2007) Standard and novel therapeutic approaches to Behçet’s disease. Drugs 67:2013–2022CrossRefPubMed
7.
Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed
8.
Lynde CB, Bruce AS, Rogers RS 3rd (2009) Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 145:273–276CrossRefPubMed
9.
Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 62:827–836PubMed
10.
Kaklamanis P, Kaklamani V (2001) Treatment of Behçet’s disease—an update. Semin Arth Rheum 30:299–312CrossRef
11.
Hatemi G, Silman A, Bang D et al (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528CrossRefPubMed
12.
Seyahi E, Fresko I, Yazici H et al (2006) The management of Behcet syndrome. Acta Rheum Port 31:125–131
13.
Lin P, Liang G (2006) Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 12:282–286CrossRefPubMed
14.
Duygulu F, Evereklioglu MM et al (2005) Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol 24:324–330CrossRefPubMed
15.
Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef
16.
Dé Tran QH, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329–335CrossRefPubMed
17.
Bruynzeel I, Van Der Raaij LM, Willemze R, Stoof TJ (1997) Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 289:189–193CrossRefPubMed
18.
Funk JO, Ernst M, Schonharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:1007–1016CrossRefPubMed
19.
Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134:1010–1016CrossRefPubMed
20.
Nakamura T, Yagi H, Kurachi K, Konno H (2006) Intestinal Behcet’s disease with pyoderma gangrenosum: a case report. World J Gastroenterol 12:979–981PubMed
21.
Fresko I, Yazici H (2008) Treatment strategies for Behçet’s disease. Expert Opin Pharmacother 9:3211–3219CrossRefPubMed
22.
Choi IJ, Kim JS, Cha SD et al (2000) Long-term clinical course and prognostic factors in intestinal Behçet’s disease. Dis Colon Rectum 43:692–700CrossRefPubMed
23.
Lee KS, Kim SJ, Lee BC et al (1997) Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 38:455–460PubMed
24.
Kurata M, Nozue M, Seino K et al (2006) Indications for surgery in intestinal Behçet’s disease. Hepatogastroenterology 53:60–63PubMed
25.
Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265CrossRefPubMed
26.
Deuter CM, Kotter I, Wallace GR et al (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136CrossRefPubMed
27.
Kaçmaz RO, Kempen JH, Newcomb C et al (2008) Systemic immunosuppressive therapy for eye diseases cohort study group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836CrossRefPubMed
28.
Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed
29.
Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285CrossRefPubMed
30.
Akman-Demir G, Ayranci O, Kurtuncu M et al (2008) Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(Suppl):S84–S90PubMed
31.
Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903PubMed
32.
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 50:256–265CrossRefPubMed
33.
Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51–ii53PubMed
34.
Elezoglou A, Kafasi N, Kaklamanis PH et al (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol 25(Suppl):S65–S69PubMed
35.
Krause L, Altenburg A, Bechrakis NE et al (2007) Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 245:1617–1621CrossRefPubMed
36.
Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet’s disease. Eur J Ophthalmol 17:191–195PubMed
37.
Sullu Y, Alotaiby H, Beden U, Erkan D (2005) Pars plana vitrectomy for ocular complications of Behçet’s disease. Ophthalmic Surg Lasers Imaging 36:292–297PubMed
38.
Soylu M, Demircan N, Pelit A (2001) Pars plana vitrectomy in ocular Behçet’s disease. Int Ophthalmol 24:219–223CrossRefPubMed
39.
Han JK, Kim HK, Kim YJ et al (2009) Behçet’s disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr 22:1269–1274CrossRefPubMed
40.
Marzban M, Mandegar MH, Karimi A et al (2008) Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg 23:765–768CrossRefPubMed
41.
Imazio M, Brucato A, Trinchero R et al (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532–539CrossRefPubMed
42.
Arishiro K, Nariyama J, Hoshiga M et al (2006) Vascular Behçet’s disease with coronary artery aneurysm. Intern Med 45:903–907CrossRefPubMed
43.
Ozen S, Bilginer Y, Besbas N et al (2010) Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169:427–430CrossRefPubMed
44.
Oh SH, Lee JH, Shin JU, Bang D (2008) Dermatological features in Behçet disease-associated vena cava obstruction. Br J Dermatol 159:555–560CrossRefPubMed
45.
Alpagut U, Ugurlucan M, Dayioglu E (2007) Major arterial involvement and review of Behçet’s disease. Ann Vasc Surg 21:232–239CrossRefPubMed
46.
Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741–749CrossRefPubMed
47.
Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol 256:513–529CrossRefPubMed
48.
Borhani Haghighi A (2009) Treatment of neuro-Behçet’s disease: an update. Expert Rev Neurother 9:565–574CrossRefPubMed
49.
Gono T, Murata M, Kawaguchi Y et al (2009) Successful treatment for sympathetic storms in a patient with neuro-Behçet’s disease. Clin Rheumatol 28:357–359CrossRefPubMed
Metadata
Title
Evaluation of current therapeutic strategies in Behçet’s disease
Authors
Iliana Alexoudi
Violetta Kapsimali
Aristides Vaiopoulos
Meletios Kanakis
George Vaiopoulos
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1566-4

Other articles of this Issue 2/2011

Clinical Rheumatology 2/2011 Go to the issue

Original Article

Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus

Brief Report

Delays in recognition and management of giant cell arteritis: results from a retrospective audit

Brief Report

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

Original Article

Kinesio taping compared to physical therapy modalities for the treatment of shoulder impingement syndrome

Case Based Review

Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature

Original Article

Spinal mobility and its impact in Moroccan patients with ankylosing spondylitis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits